Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial-Reference-Cited by-同舟云学术

Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial

Published:2023-02 Issue:2 Volume:11 Page:109-119
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Ray Kausik K,Troquay Roel P T,Visseren Frank L J,Leiter Lawrence A,Scott Wright R,Vikarunnessa Sheikh,Talloczy Zsolt,Zang Xiao,Maheux Pierre,Lesogor Anastasia,Landmesser Ulf

Funder

Novartis

NIHR Imperial Biomedical Research Centre

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference28 articles.

1. Implications of ACC/AHA versus ESC/EAS LDL-C recommendations for residual risk reduction in ASCVD: a simulation study from DA VINCI;Vallejo-Vaz;Cardiovasc Drugs Ther,2022

2. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis;Ference;J Am Coll Cardiol,2012

3. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study;Ray;Eur J Prev Cardiol,2021

4. Evolocumab and clinical 0utcomes in patients with cardiovascular disease;Sabatine;N Engl J Med,2017

5. Alirocumab and cardiovascular outcomes after acute coronary syndrome;Schwartz;N Engl J Med,2018

Cited by 129 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gene therapy for polygenic or complex diseases;Biomarker Research;2024-09-04

2. Recent progress in gene therapy for familial hypercholesterolemia treatment;iScience;2024-09

3. Review of Recent Literature and Updates in Nonstatin Cholesterol Management;Mayo Clinic Proceedings;2024-09

4. Post-marketing pharmacovigilance study of inclisiran: mining and analyzing adverse event data from the FDA Adverse Event Reporting System database;International Journal of Clinical Pharmacy;2024-08-27

5. Established and Emerging Nucleic Acid Therapies for Familial Hypercholesterolemia;Circulation;2024-08-27